These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32273545)

  • 41. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma.
    Tsvankin V; Hashizume R; Katagi H; Herndon JE; Lascola C; Venkatraman TN; Picard D; Burrus B; Becher OJ; Thompson EM
    Neurosurgery; 2020 May; 86(5):742-751. PubMed ID: 31225627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
    Chen J; Lin Z; Barrett L; Dai L; Qin Z
    Bioorg Chem; 2020 Jun; 99():103847. PubMed ID: 32311581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.
    Pacifici M; Shore EM
    Cytokine Growth Factor Rev; 2016 Feb; 27():93-104. PubMed ID: 26776312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adult diffuse intrinsic pontine glioma: clinical, radiological, pathological, molecular features, and treatments of 96 patients.
    Wang Y; Pan C; Xie M; Zuo P; Li X; Gu G; Li T; Jiang Z; Wu Z; Zhang J; Zhang L
    J Neurosurg; 2022 Dec; 137(6):1628-1638. PubMed ID: 35395636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.
    Taylor KR; Mackay A; Truffaux N; Butterfield Y; Morozova O; Philippe C; Castel D; Grasso CS; Vinci M; Carvalho D; Carcaboso AM; de Torres C; Cruz O; Mora J; Entz-Werle N; Ingram WJ; Monje M; Hargrave D; Bullock AN; Puget S; Yip S; Jones C; Grill J
    Nat Genet; 2014 May; 46(5):457-461. PubMed ID: 24705252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ACVR1 Function in Health and Disease.
    Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
    Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
    [No Abstract]   [Full Text] [Related]  

  • 48. Radiogenomics of diffuse intrinsic pontine gliomas (DIPGs): correlation of histological and biological characteristics with multimodal MRI features.
    Calmon R; Dangouloff-Ros V; Varlet P; Deroulers C; Philippe C; Debily MA; Castel D; Beccaria K; Blauwblomme T; Grevent D; Levy R; Roux CJ; Purcell Y; Saitovitch A; Zilbovicius M; Dufour C; Puget S; Grill J; Boddaert N
    Eur Radiol; 2021 Dec; 31(12):8913-8924. PubMed ID: 34003354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
    Sekimata K; Sato T; Sakai N
    Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
    Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
    Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.
    Aziz-Bose R; Monje M
    Curr Opin Oncol; 2019 Nov; 31(6):522-530. PubMed ID: 31464759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
    Erker C; Lane A; Chaney B; Leary S; Minturn JE; Bartels U; Packer RJ; Dorris K; Gottardo NG; Warren KE; Broniscer A; Kieran MW; Zhu X; White P; Dexheimer PJ; Black K; Asher A; DeWire M; Hansford JR; Gururangan S; Nazarian J; Ziegler DS; Sandler E; Bartlett A; Goldman S; Shih CS; Hassall T; Dholaria H; Bandopadhayay P; Samson Y; Monje M; Fisher PG; Dodgshun A; Parkin S; Chintagumpala M; Tsui K; Gass D; Larouche V; Broxson E; Garcia Lombardi M; Wang SS; Ma J; Hawkins C; Hamideh D; Wagner L; Koschmann C; Fuller C; Drissi R; Jones BV; Leach J; Fouladi M
    Neuro Oncol; 2022 Jan; 24(1):141-152. PubMed ID: 34114629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
    Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
    Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
    Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
    Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma.
    Ishida J; Alli S; Bondoc A; Golbourn B; Sabha N; Mikloska K; Krumholtz S; Srikanthan D; Fujita N; Luck A; Maslink C; Smith C; Hynynen K; Rutka J
    J Control Release; 2021 Feb; 330():1034-1045. PubMed ID: 33188825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications.
    Buczkowicz P; Bartels U; Bouffet E; Becher O; Hawkins C
    Acta Neuropathol; 2014 Oct; 128(4):573-81. PubMed ID: 25047029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.
    Truffaux N; Philippe C; Paulsson J; Andreiuolo F; Guerrini-Rousseau L; Cornilleau G; Le Dret L; Richon C; Lacroix L; Puget S; Geoerger B; Vassal G; Östman A; Grill J
    Neuro Oncol; 2015 Jul; 17(7):953-64. PubMed ID: 25534822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
    Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
    Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.